Innovation Kyoto 2021 Investment Limited Partnership ("KYOTO-iCAP No.2 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto-iCAP") (Head office: Sakyo-ku, Kyoto; Representative Director: Ko Kusumi) as the general partner, has made a follow-on investment in RadioNano Therapeutics Inc. ("RadioNano Tx" Head office: Sakyo-ku, Kyoto; Representative Director: Masatoshi Chiba) through a third-party allocation of new shares.

Overview of this investment
RadioNano Tx was established in April 2024 by CEO Masatoshi Chiba and Director Hiroshi Kawai under the auspices of Kyoto-iCAP, with the aim of implementing BNCT (Boron Neutron Capture Therapy) using novel highly hydrophilic boron-containing inorganic nanoparticles (RN-501) developed by Professor Naoki Komatsu Graduate School of Human and Environmental Studies, Kyoto University, and Professor Minoru Suzuki, Composite Nuclear Science Institute, Kyoto University, for social benefit.

In addition to the joint research conducted by Professor Komatsu and Professor Suzuki, Kyoto University has been validating the feasibility of establishing the start-up and demonstrating that RN-501 induces potent cancer cell killing and enhances cancer immune activity as a cancer therapeutic agent for BNCT. This research was also supported by the "feasibility study" R&D fund under the National Institute of Science and Technology Agency's New Industry Creation Fund for University-Launched Science and Technology project.

RadioNano Tx has inherited these research results from Kyoto University and has established a research and development system for boron inorganic particles optimized for BNCT, with Prof. Komatsu and Prof. Suzuki as scientific and technical advisors. With this funding, the company aims to proceed with non-clinical study for RN-501 clinical trials.

Kyoto-iCAP has made a follow-on investment of ¥200 million, anticipating that RN-501 and its underlying technology, developed by Kyoto University and RadioNano Tx, will provide new therapeutic options for cancer treatment. In addition to Kyoto-iCAP, Mitsubishi UFJ Capital Limited, DBJ Capital Limited, and the Japan Science and Technology Agency participated in the third-party allocation of new shares conducted by RadioNano Tx, which approximately ¥450 million. Additional funding is planned for around the end of the year and discussions are currently underway with several investors.

RadioNano TherapeuticsAbout the Corporation
Establishment : April 1, 2024
Nature of Business: Research and development of highly hydrophilic inorganic nanoparticle products
Head Office: 36-1, Yoshida Honmachi, Sakyo-ku, Kyoto, Japan
Representative Director : Masatoshi Chiba, PhD
HP :https://www.radionano-tx.com/en

Kyoto University Innovation Capital Corporation (Kyoto) iCAPAbout
As a wholly-owned subsidiary of Kyoto University, Kyoto iCAP invests in and provides other business support to companies that utilize research results generated at Kyoto University and other national universities. The firm currently operates the Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-iCAP No. 1 Fund") (established in January 2016) with a total value of ¥16 billion and the KYOTO-iCAP No. 2 Fund (established in January 2021) with a total value of ¥18.1 billion. The KYOTO-iCAP 1 Fund has a maturity of up to 20 years, and the KYOTO-iCAP 2 Fund has a maturity of up to 17 years, enabling long-term support for the practical application of research results from Kyoto University, which has strengths in basic research. The KYOTO-iCAP 2 Fund has a maximum maturity of 17 years. In addition, a portion of the KYOTO-iCAP No. 2 Fund will be invested in national university-launched ventures outside of Kyoto University.

Contact information for inquiries
Kyoto University Innovation Capital Co., Ltd.
36-1, Yoshida Honmachi, Sakyo-ku, Kyoto 606-8317, Japan
Osami Kono, Senior Officer, Business Development Department
E-mail:info@kyoto-icap.co.jp
TEL: 075-753-7588